# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $4 price target.
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR Patients remain...
MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializ...
HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $4 price target.
Citigroup analyst Yigal Nochomovitz maintains Macrogenics (NASDAQ:MGNX) with a Buy and lowers the price target from $16 to $14.
BMO Capital analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Market Perform and lowers the price target from ...
Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.59)...